Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation
Completed
Conditions studied: Osteoporosis
In brief
Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures. The cause of bone loss is not known. We believe that TZD may cause increased accumulation of fat in the bone marrow, which may cause decrease bone formation and weak bones. .
Key facts
- Study ID
- NCT00663143
- Run by
- Emory University
- People needed
- 9
- Starts
- 2009-07-01
- Expected to finish
- 2010-12-01
- Last updated by the study team
- 2015-04-01
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Males or females between the ages of 18 and 80 years undergoing ileac crest bone graft to repair traumatic mandible fracture.
- Patients admitted for elective or emergency surgery or trauma.
You may not qualify if…
- Subjects with history of decompensated diabetes (blood glucose > 200 mg/dl)
- Critically ill patients with multi-organ failure, relevant hepatic disease or impaired renal function (serum creatinine ≥ 2.0 mg/dl)
- HIV
- Hemolytic anemia and/or hematocrit < 28%
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- Pregnancy
Where it is running
- Grady Memorial Hospital — Atlanta, Georgia, United States
- Emory Crawford Long Hospital — Atlanta, Georgia, United States
- Emory University Hospital — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.